Agenus Competitors

Amgen (NASDAQ:AMGN) and Agenus (NASDAQ:AGEN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, risk, analyst recommendations, dividends, institutional ownership and profitability.

Analyst Ratings

This is a breakdown of recent ratings for Amgen and Agenus, as provided by MarketBeat.

Amgen currently has a consensus target price of $257.3043, indicating a potential upside of 15.95%. Agenus has a consensus target price of $8.00, indicating a potential upside of 153.16%. Given Agenus' stronger consensus rating and higher probable upside, analysts plainly believe Agenus is more favorable than Amgen.

Earnings and Valuation

This table compares Amgen and Agenus' gross revenue, earnings per share and valuation.

Amgen has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Amgen has a beta of 0.76, suggesting that its stock price is 24% less volatile than the S&P 500. Comparatively, Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500.

Institutional & Insider Ownership

75.2% of Amgen shares are held by institutional investors. Comparatively, 53.4% of Agenus shares are held by institutional investors. 0.4% of Amgen shares are held by insiders. Comparatively, 4.7% of Agenus shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Amgen and Agenus' net margins, return on equity and return on assets.

Summary

Amgen beats Agenus on 10 of the 14 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and Gilead Sciences (NASDAQ:GILD) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Agenus and Gilead Sciences, as provided by MarketBeat.com.

Agenus presently has a consensus target price of $8.00, indicating a potential upside of 153.16%. Gilead Sciences has a consensus target price of $96.0370, indicating a potential upside of 51.89%. Given Agenus' stronger consensus rating and higher probable upside, equities analysts plainly believe Agenus is more favorable than Gilead Sciences.

Valuation and Earnings

This table compares Agenus and Gilead Sciences' gross revenue, earnings per share and valuation.

Gilead Sciences has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Gilead Sciences, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Gilead Sciences has a beta of 0.51, suggesting that its stock price is 49% less volatile than the S&P 500.

Institutional and Insider Ownership

53.4% of Agenus shares are held by institutional investors. Comparatively, 76.4% of Gilead Sciences shares are held by institutional investors. 4.7% of Agenus shares are held by insiders. Comparatively, 0.1% of Gilead Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Agenus and Gilead Sciences' net margins, return on equity and return on assets.

Summary

Gilead Sciences beats Agenus on 9 of the 14 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Agenus and Vertex Pharmaceuticals, as provided by MarketBeat.com.

Agenus presently has a consensus target price of $8.00, indicating a potential upside of 153.16%. Vertex Pharmaceuticals has a consensus target price of $292.68, indicating a potential upside of 40.85%. Given Agenus' stronger consensus rating and higher probable upside, equities analysts plainly believe Agenus is more favorable than Vertex Pharmaceuticals.

Valuation and Earnings

This table compares Agenus and Vertex Pharmaceuticals' gross revenue, earnings per share and valuation.

Vertex Pharmaceuticals has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Vertex Pharmaceuticals has a beta of 0.79, suggesting that its stock price is 21% less volatile than the S&P 500.

Institutional and Insider Ownership

53.4% of Agenus shares are held by institutional investors. Comparatively, 92.2% of Vertex Pharmaceuticals shares are held by institutional investors. 4.7% of Agenus shares are held by insiders. Comparatively, 0.7% of Vertex Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Agenus and Vertex Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Vertex Pharmaceuticals beats Agenus on 11 of the 15 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Agenus and Regeneron Pharmaceuticals, as provided by MarketBeat.com.

Agenus presently has a consensus target price of $8.00, indicating a potential upside of 153.16%. Regeneron Pharmaceuticals has a consensus target price of $625.8077, indicating a potential upside of 39.26%. Given Agenus' stronger consensus rating and higher probable upside, equities analysts plainly believe Agenus is more favorable than Regeneron Pharmaceuticals.

Valuation and Earnings

This table compares Agenus and Regeneron Pharmaceuticals' gross revenue, earnings per share and valuation.

Regeneron Pharmaceuticals has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.3, suggesting that its stock price is 70% less volatile than the S&P 500.

Institutional and Insider Ownership

53.4% of Agenus shares are held by institutional investors. Comparatively, 85.0% of Regeneron Pharmaceuticals shares are held by institutional investors. 4.7% of Agenus shares are held by insiders. Comparatively, 11.8% of Regeneron Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Agenus and Regeneron Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Regeneron Pharmaceuticals beats Agenus on 12 of the 15 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and Biogen (NASDAQ:BIIB) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Agenus and Biogen, as provided by MarketBeat.com.

Agenus presently has a consensus target price of $8.00, indicating a potential upside of 153.16%. Biogen has a consensus target price of $304.4667, indicating a potential upside of 15.52%. Given Agenus' stronger consensus rating and higher probable upside, equities analysts plainly believe Agenus is more favorable than Biogen.

Valuation and Earnings

This table compares Agenus and Biogen's gross revenue, earnings per share and valuation.

Biogen has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Biogen has a beta of 0.53, suggesting that its stock price is 47% less volatile than the S&P 500.

Institutional and Insider Ownership

53.4% of Agenus shares are held by institutional investors. Comparatively, 83.5% of Biogen shares are held by institutional investors. 4.7% of Agenus shares are held by insiders. Comparatively, 0.5% of Biogen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Agenus and Biogen's net margins, return on equity and return on assets.

Summary

Biogen beats Agenus on 9 of the 14 factors compared between the two stocks.

Agenus (NASDAQ:AGEN) and Alexion Pharmaceuticals (NASDAQ:ALXN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, analyst recommendations, valuation, institutional ownership and profitability.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Agenus and Alexion Pharmaceuticals, as provided by MarketBeat.com.

Agenus presently has a consensus target price of $8.00, indicating a potential upside of 153.16%. Alexion Pharmaceuticals has a consensus target price of $153.1250, indicating a potential upside of 3.14%. Given Agenus' stronger consensus rating and higher probable upside, equities analysts plainly believe Agenus is more favorable than Alexion Pharmaceuticals.

Valuation and Earnings

This table compares Agenus and Alexion Pharmaceuticals' gross revenue, earnings per share and valuation.

Alexion Pharmaceuticals has higher revenue and earnings than Agenus. Agenus is trading at a lower price-to-earnings ratio than Alexion Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Agenus has a beta of 1.86, suggesting that its stock price is 86% more volatile than the S&P 500. Comparatively, Alexion Pharmaceuticals has a beta of 1.33, suggesting that its stock price is 33% more volatile than the S&P 500.

Institutional and Insider Ownership

53.4% of Agenus shares are held by institutional investors. Comparatively, 87.3% of Alexion Pharmaceuticals shares are held by institutional investors. 4.7% of Agenus shares are held by insiders. Comparatively, 4.0% of Alexion Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Agenus and Alexion Pharmaceuticals' net margins, return on equity and return on assets.

Summary

Alexion Pharmaceuticals beats Agenus on 11 of the 15 factors compared between the two stocks.